IGF-1 LR3 vs CJC-1295 + Ipamorelin: Direct vs Stimulated Growth

IGF-1 LR3 and the CJC-1295 + Ipamorelin stack represent two fundamentally different approaches to growth factor research. IGF-1 LR3 is a long-acting analog of insulin-like growth factor 1 — the downstream effector hormone that mediates many of GH's anabolic effects. It bypasses the GH axis entirely and delivers IGF-1 directly. CJC-1295 + Ipamorelin stimulates the pituitary to release GH naturally, which then triggers hepatic IGF-1 production through the normal physiological cascade. The choice between them reflects whether the research requires direct hormone delivery or preserved axis function in test subjects. For research purposes only.

IGF-1 LR3: A 83-amino-acid analog of IGF-1 with an arginine substitution at position 3 and a 13-amino-acid extension at the N-terminus. These modifications reduce binding to IGF binding proteins (IGFBPs), increasing bioavailability and extending half-life to 20-30 hours. Directly activates IGF-1 receptors on muscle, bone, and other tissues without requiring GH secretion. CJC-1295 + Ipamorelin: CJC-1295 (GHRH analog) amplifies GH pulses while Ipamorelin (GH secretagogue) initiates them. The combined GH release triggers natural hepatic IGF-1 production. This preserves the feedback loops that regulate GH/IGF-1 levels and maintains pulsatile release patterns in test subjects.

Approach: IGF-1 LR3 = Direct hormone delivery | CJC+Ipa = Stimulated natural release GH axis suppression: IGF-1 LR3 = Yes (negative feedback) | CJC+Ipa = No (enhances axis) Dose: IGF-1 LR3 = 20-50 mcg daily | CJC+Ipa = 100 mcg each, 1-3x daily Half-life: IGF-1 LR3 = 20-30 hours | CJC+Ipa = ~30 minutes (pulse) Hypoglycaemia risk: IGF-1 LR3 = Significant | CJC+Ipa = Minimal Muscle-specific effects: IGF-1 LR3 = Strong (local injection) | CJC+Ipa = Systemic Safety profile: IGF-1 LR3 = Higher risk | CJC+Ipa = Lower risk Cycle length: IGF-1 LR3 = 4-6 weeks max | CJC+Ipa = 12-16 weeks Cost: IGF-1 LR3 = High (1mg vials) | CJC+Ipa = Moderate Physiological: IGF-1 LR3 = No (supraphysiological) | CJC+Ipa = Yes (natural pattern)

Choose IGF-1 LR3 when: The research specifically investigates direct IGF-1 receptor activation, local muscle growth effects are the objective (site-specific injection), or the study requires bypassing the GH axis entirely in test subjects. Note: IGF-1 LR3 carries higher risk due to hypoglycaemia potential and GH axis suppression. Choose CJC-1295 + Ipamorelin when: The protocol aims to enhance natural GH/IGF-1 production without axis suppression, long-term (12-16 week) protocols are planned, safety is prioritised, or the research investigates pituitary GH secretion capacity in test subjects. The CJC-1295 + Ipamorelin stack is far more commonly used in research due to its superior safety profile and preservation of natural axis function. IGF-1 LR3 is reserved for specific research questions requiring direct IGF-1 delivery. For research purposes only.